InsiderTrades.com logo
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
From Paradigm Press   |   Ad
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Click here to find out that this 8,788% cryptocurrency is.

ELVN Insider Trading

Insider Ownership Percentage: 45.80%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $24,491,184.71

Enliven Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Enliven Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Enliven Therapeutics Share Price & Price History

Current Price: $17.18
Price Change: ▲ Price Increase of +0.4 (2.38%)
As of 04/26/2024 01:00 AM ET

This chart shows the closing price history over time for ELVN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
From Paradigm Press   |   Ad
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Click here to find out that this 8,788% cryptocurrency is.

Enliven Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/15/2024Richard A HeymanDirectorSell1,270$19.99$25,387.30137,155View SEC Filing Icon  
4/11/2024Anish PatelCOOSell17,500$25.03$438,025.00View SEC Filing Icon  
4/11/2024Benjamin HohlCFOSell14,000$24.72$346,080.00View SEC Filing Icon  
4/11/2024Joseph P. LyssikatosinsiderSell30,000$25.04$751,200.00View SEC Filing Icon  
4/11/2024Rahul D BallalDirectorSell53,400$23.95$1,278,930.0022,341View SEC Filing Icon  
4/11/2024Samuel KintzCEOSell47,709$25.04$1,194,633.36View SEC Filing Icon  
4/8/2024Anish PatelCOOSell4,875$18.60$90,675.002,597View SEC Filing Icon  
4/4/2024Rahul D BallalDirectorSell3,485$19.15$66,737.7522,341View SEC Filing Icon  
4/1/2024Joseph P. LyssikatosinsiderSell12,000$18.60$223,200.00View SEC Filing Icon  
4/1/2024Rahul D BallalDirectorSell3,237$19.08$61,761.9622,341View SEC Filing Icon  
3/27/2024Benjamin HohlCFOSell3,250$18.25$59,312.50View SEC Filing Icon  
3/25/2024Samuel KintzCEOSell12,000$17.56$210,720.00View SEC Filing Icon  
3/19/2024Richard A HeymanDirectorSell1,270$14.50$18,415.00143,470View SEC Filing Icon  
3/6/2024Anish PatelCOOSell4,875$15.64$76,245.007,472View SEC Filing Icon  
2/29/2024Joseph P. LyssikatosinsiderSell12,000$16.42$197,040.00View SEC Filing Icon  
2/27/2024Benjamin HohlCFOSell3,250$16.97$55,152.50View SEC Filing Icon  
2/15/2024Richard A HeymanDirectorSell1,270$17.42$22,123.40144,740View SEC Filing Icon  
2/6/2024Anish PatelCOOSell4,875$15.11$73,661.2512,347View SEC Filing Icon  
1/31/20245Am Partners Vi, LlcMajor ShareholderSell500,000$15.00$7,500,000.00771,983View SEC Filing Icon  
1/30/2024Richard A HeymanDirectorSell1,270$16.41$20,840.70146,010View SEC Filing Icon  
1/29/2024Benjamin HohlCFOSell3,250$15.81$51,382.50View SEC Filing Icon  
1/29/2024Joseph P. LyssikatosinsiderSell12,000$15.85$190,200.00View SEC Filing Icon  
1/25/2024Samuel KintzCEOSell12,000$15.69$188,280.00View SEC Filing Icon  
1/22/2024Anish PatelCOOSell4,875$15.13$73,758.7517,222View SEC Filing Icon  
1/2/2024Anish PatelCOOSell11,000$15.00$165,000.0022,097View SEC Filing Icon  
1/2/2024Benjamin HohlCFOSell9,383$15.01$140,838.83View SEC Filing Icon  
12/26/2023Anish PatelCOOSell102$15.01$1,531.0235,637View SEC Filing Icon  
12/26/2023Benjamin HohlCFOSell100$15.00$1,500.00View SEC Filing Icon  
12/26/2023Samuel KintzCEOSell12,000$14.64$175,680.00View SEC Filing Icon  
12/22/2023Anish PatelCOOSell983$15.03$14,774.4935,739View SEC Filing Icon  
12/22/2023Benjamin HohlCFOSell1,030$15.07$15,522.10View SEC Filing Icon  
12/22/2023Samuel KintzCEOSell8,175$13.05$106,683.75View SEC Filing Icon  
12/21/2023Joseph P. LyssikatosinsiderSell20$13.00$260.00View SEC Filing Icon  
12/21/2023Richard A HeymanDirectorSell7$13.00$91.00147,448View SEC Filing Icon  
12/20/2023Samuel KintzCEOSell7,779$13.01$101,204.79View SEC Filing Icon  
12/19/2023Joseph P. LyssikatosinsiderSell200$13.00$2,600.00View SEC Filing Icon  
12/19/2023Richard A HeymanDirectorSell255$13.00$3,315.00149,565View SEC Filing Icon  
11/3/2023Joseph P. LyssikatosinsiderSell8,546$13.08$111,781.68View SEC Filing Icon  
11/3/2023Samuel KintzCEOSell8,026$13.08$104,980.08View SEC Filing Icon  
9/29/2023Joseph P. LyssikatosinsiderSell12,000$13.62$163,440.00View SEC Filing Icon  
9/26/20235Am Partners Vi, LlcMajor ShareholderSell197,500$15.00$2,962,500.00854,796View SEC Filing Icon  
9/25/2023Samuel KintzCEOSell12,000$13.81$165,720.00View SEC Filing Icon  
8/24/20235Am Partners Vi, LlcMajor ShareholderSell440,000$16.00$7,040,000.00887,507View SEC Filing Icon  
See Full Table
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
From Paradigm Press   |   Ad
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Click here to find out that this 8,788% cryptocurrency is.

SEC Filings (Institutional Ownership Changes) for Enliven Therapeutics (NASDAQ:ELVN)

95.08% of Enliven Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ELVN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Enliven Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/13/2024Tower Research Capital LLC TRC5,485$76K0.0%-18.8%0.013%Search for SEC Filing on Google Icon
2/6/2024AJOVista LLC2,046$28K0.0%N/A0.005%Search for SEC Filing on Google Icon
2/6/2024Swiss National Bank36,473$0.51M0.0%-10.3%0.089%Search for SEC Filing on Google Icon
1/24/2024Mirae Asset Global Investments Co. Ltd.12,305$0.17M0.0%+9.1%0.030%Search for SEC Filing on Google Icon
1/24/2024China Universal Asset Management Co. Ltd.4,763$66K0.0%N/A0.012%Search for SEC Filing on Google Icon
1/12/2024SG Americas Securities LLC13,501$0.19M0.0%+17.8%0.033%Search for SEC Filing on Google Icon
1/5/2024Exchange Traded Concepts LLC8,708$0.12M0.0%+34.0%0.021%Search for SEC Filing on Google Icon
12/6/2023Citigroup Inc.3,347$46K0.0%-69.1%0.008%Search for SEC Filing on Google Icon
11/13/2023FMR LLC3,676,213$50.22M0.0%-8.1%8.923%Search for SEC Filing on Google Icon
11/8/2023Swiss National Bank40,673$0.56M0.0%-17.3%0.099%Search for SEC Filing on Google Icon
11/7/2023Barclays PLC13,629$0.19M0.0%-8.1%0.033%Search for SEC Filing on Google Icon
10/23/2023BML Capital Management LLC50,000$0.68M0.6%-32.6%0.121%Search for SEC Filing on Google Icon
10/13/2023SG Americas Securities LLC11,460$0.16M0.0%N/A0.028%Search for SEC Filing on Google Icon
8/15/2023HighVista Strategies LLC121,073$2.47M1.1%N/A0.294%Search for SEC Filing on Google Icon
8/15/2023Commodore Capital LP2,348,272$47.93M5.4%+35.6%5.707%Search for SEC Filing on Google Icon
8/11/2023VR Adviser LLC2,230,127$45.52M7.3%+0.7%5.423%Search for SEC Filing on Google Icon
8/10/2023Metropolitan Life Insurance Co NY1,279$26K0.0%N/A0.003%Search for SEC Filing on Google Icon
8/4/2023American International Group Inc.11,235$0.23M0.0%N/A0.027%Search for SEC Filing on Google Icon
8/3/2023Bank of New York Mellon Corp80,924$1.65M0.0%+429.1%0.197%Search for SEC Filing on Google Icon
8/2/2023Bank of Montreal Can191,893$3.95M0.0%N/A0.467%Search for SEC Filing on Google Icon
7/24/2023BML Capital Management LLC74,232$1.52M1.4%-65.0%0.181%Search for SEC Filing on Google Icon
7/20/2023Exchange Traded Concepts LLC6,934$0.14M0.0%N/A0.017%Search for SEC Filing on Google Icon
7/18/2023Denali Advisors LLC9,900$0.20M0.1%N/A0.024%Search for SEC Filing on Google Icon
6/1/2023Prelude Capital Management LLC34,062$40K0.0%N/A0.519%Search for SEC Filing on Google Icon
5/16/2023Fairmount Funds Management LLC1,924,938$42.16M7.2%N/A29.353%Search for SEC Filing on Google Icon
5/16/2023Boxer Capital LLC710,644$15.56M0.8%N/A10.836%Search for SEC Filing on Google Icon
5/15/2023Commodore Capital LP1,731,365$37.92M5.8%N/A26.401%Search for SEC Filing on Google Icon
5/15/2023Logos Global Management LP401,229$8.79M1.3%N/A6.118%Search for SEC Filing on Google Icon
5/12/2023Mirabella Financial Services LLP11,670$0.26M0.0%N/A0.178%Search for SEC Filing on Google Icon
5/11/2023FMR LLC3,163,482$69.28M0.0%N/A48.239%Search for SEC Filing on Google Icon
4/20/2023Dorsey Wright & Associates1,237$27K0.0%N/A0.019%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Enliven Therapeutics logo
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.
Read More on Enliven Therapeutics

Today's Range

Now: $17.18
Low: $16.16
High: $17.52

50 Day Range

MA: $17.12
Low: $11.54
High: $23.82

52 Week Range

Now: $17.18
Low: $9.80
High: $26.00

Volume

148,934 shs

Average Volume

500,130 shs

Market Capitalization

$804.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06

Who are the company insiders with the largest holdings of Enliven Therapeutics?

Enliven Therapeutics' top insider investors include:
  1. 5Am Partners Vi, Llc (Major Shareholder)
  2. Richard A Heyman (Director)
  3. Anish Patel (COO)
  4. Rahul D Ballal (Director)
  5. Benjamin Hohl (CFO)
  6. Joseph P Lyssikatos (Insider)
  7. Samuel Kintz (CEO)
Learn More about top insider investors at Enliven Therapeutics.
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
From Paradigm Press   |   Ad
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Click here to find out that this 8,788% cryptocurrency is.